TLRY:NGS-Tilray Inc.

EQUITY | Drug Manufacturers | Nasdaq Global Select

Last Closing

USD 41.05

Change

+0.64 (+1.58)%

Market Cap

USD 3.99B

Volume

1.23M

Analyst Target

USD 98.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-06-18 )

Largest Industry Peers for Drug Manufacturers

ETFs Containing TLRY

HMMJ:CA Horizons Marijuana Life S.. 11.09 % 0.86 %

-0.21 (0%)

CAD 0.08B
MJ Amplify Alternative Harve.. 8.56 % 0.75 %

-0.12 (0%)

USD 0.23B
BUDX 5.76 % 0.00 %

N/A

N/A
SEED:CA 0.00 % 1.13 %

N/A

N/A
YOLO AdvisorShares Pure Cannab.. 0.00 % 0.00 %

-0.04 (0%)

USD 0.05B
HMMJ-U:CA Horizons Marijuana Life S.. 0.00 % 0.00 %

+0.15 (+0%)

CAD 0.08B
CNBS Amplify Seymour Cannabis .. 0.00 % 0.00 %

-0.12 (0%)

USD 0.03B
THCX 0.00 % 0.00 %

N/A

N/A
MJJ 0.00 % 0.00 %

N/A

N/A
MJO 0.00 % 0.00 %

N/A

N/A
MJX 0.00 % 0.00 %

N/A

N/A
POTX 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -41.81% 10% F 6% D-
Dividend Return N/A N/A N/A N/A F
Total Return -41.81% 10% F 6% D-
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A F
Dividend Return N/A N/A N/A N/A F
Total Return N/A N/A N/A N/A F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A F
Dividend Return N/A N/A N/A N/A F
Total Return N/A N/A N/A N/A F
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A F
Dividend Return N/A N/A N/A N/A F
Total Return N/A N/A N/A N/A F
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A F
Risk Adjusted Return N/A N/A N/A N/A F
Market Capitalization 3.99B 86% B+ 88% B+

Key Financial Ratios

  Ratio vs. Industry/Classification (Drug Manufacturers) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -69.58 93% 95%
Price/Book Ratio 20.32 6% 5%
Price / Cash Flow Ratio -21.05 96% 97%
Price/Free Cash Flow Ratio -55.47 93% 94%
Management Effectiveness  
Return on Equity -58.43% 44% 18%
Return on Invested Capital -26.09% 56% 29%
Return on Assets -24.77% 51% 23%
Debt to Equity Ratio 126.25% 23% 19%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector